Deflux® (NASHA TM /Dx) urethral bulking injections: Outcomes over a decade in women with stress urinary incontinence

Abstract

Objectives:

Urethral bulking injections are thought to be a low risk minimally invasive but temporary treatment option for women with stress urinary incontinence (SUI) with increasing prominence especially in the current era of the mesh controversy. However, little is known about their long-term effects. This study aims to evaluate the efficacy and long-term outcomes of Deflux®, a non-animal stabilised hyaluronic acid/dextranomer (NASHA^TM/Dx) gel, when used as a urethral bulking agent in the treatment of SUI in women.

Methods:

All women with SUI treated with Deflux® from 2001 to 2007 were analysed. The success rates, duration of efficacy and short- and long-term complications of the treatment were recorded.

Results:

A total of 142 women with a follow-up of up to 13 years (mean 8.8 years) were included. Subjective treatment success was achieved in 92/142 (65%) patients. In those who achieved continence, the mean efficacy was 4.7 years. Side effects were uncommon with 12 (6%) of 209 experiencing transient urinary retention and 11 (5%) of 209 experiencing pseudocyst formation. All pseudocysts were treated successfully with an incision and drainage under either general or local anaesthetic. Sixty (42%) of 142 patients went on to have subsequent definitive incontinence surgery, and Deflux® treatment was found not to have negatively impacted the operation.

Conclusion:

Deflux® urethral bulking injections appear to be efficacious and safe when used as a treatment for SUI in women with a longer duration of efficacy than previously thought and a low side effect profile. This study provides a valuable timeline to help manage the expectations of patients considering urethral bulking treatment.

Level of evidence:

Keywords

Urinary incontinence stress incontinence female urology urethral bulking endoscopy

Get full access to this article

View all access options for this article.

References

National Institute for Health and Clinical Excellence. Intramural urethral bulking procedures for stress urinary incontinence in women (IPG 138). London: NICE, 2005.

Abrams

Cardozo

Khoury

, et al. Incontinence. 5th ed. Paris: ICUD-EAU, 2013, pp. 27–28.

Keegan

Atiemo

Cody

, et al. Periurethral injection therapy for urinary incontinence in women. Cochrane Database Syst Rev 2007; 3: CD003881.

Kirchin

Page

Keegan

, et al. Urethral injection therapy for urinary incontinence in women. Cochrane Database Syst Rev 2012; 2: CD003881.

Kershen

Dmochowski

Appell

. Beyond collagen: Injectable therapies for the treatment of female stress urinary incontinence in the new millennium. Urol Clin North Am 2002; 29(3): 559–574.

Chapple

Wein

Brubaker

, et al. Stress incontinence injection therapy: What is best for our patients? Eur Urol 2005; 48(4): 552–565.

Wise

. Surgical mesh for stress urinary incontinence to be halted immediately in England. BMJ 2018; 362: k3035.

Blick

Marsh

Muneer

, et al. NASHA/Dx Gel (ZuidexTM) for stress urinary incontinence: Results from a single-centre study of 150 patients. Curr Urol 2008; 2: 194–199.

Stenberg

Larsson

Johnson

, et al. DiHA dextran copolymer, a new biocompatible material for endoscopic treatment of stress incontinent women. Short term results. Acta Obstet Gynecol Scand 1999; 78(5): 436–442.

10.

National Institute for Health and Clinical Excellence. Urinary incontinence in women: Management (CG171). London: NICE, 2015.

11.

Lucas

Bedretdinova

Berghmans

, et al. Guidelines on urinary incontinence. Arnhem: EAU, 2015, p. 42.

12.

Winters

Chiverton

Scarpero

, et al. Collagen injection therapy in elderly women: Long-term results and patient satisfaction. Urology 2000; 55(6): 856–861.

13.

Ghoniem

Miller

. A systematic review and meta-analysis of Macroplastique for treating female stress urinary incontinence. Int Urogynecol J 2013; 24(1): 27–36.

14.

Andersen

. Long-term follow-up comparison of durasphere and contigen in the treatment of stress urinary incontinence. J Low Genit Tract Dis 2002; 6(4): 239–243.

15.

Pai

Al-Singary

. Durability, safety and efficacy of polyacrylamide hydrogel (Bulkamid®) in the management of stress and mixed urinary incontinence: Three year follow up outcomes. Cent European J Urol 2015; 68(4): 428–433.

16.

Maher

O’Reilly

Dwyer

, et al. Pubovaginal sling versus transurethral Macroplastique for stress urinary incontinence and intrinsic deficiency: A prospective randomised controlled trial. BJOG 2005; 112(6): 797–801.

17.

Mouritsen

Lose

Moller-Bek

. Long-term follow-up after urethral injection with polyacrylamide hydrogel for female stress incontinence. Acta Obstet Gynecol Scand 2014; 93(2): 209–212.

18.

Lightner

Rovner

Corcos

, et al. Randomized controlled multisite trial of injected bulking agents for women with intrinsic sphincter deficiency: Mid-urethral injection of Zuidex via the Implacer versus proximal urethral injection of contigen cystoscopically. Urology 2009; 74(4): 771–775.

19.

Hagemeier

Blau

Gauruder-Burmester

, et al. Paraurethral abscess developing after mid-urethral Zuidex-injection in women with stress urinary incontinence – management of complications and retrospective comparison with bladder neck located injection technique. Zentralbl Gynäkol 2006; 128: 68–70.

20.

Blick

Patel

Foley

. Do periurethral Zuidex injections alter the performance of tension-free tapes in the treatment of stress urinary incontinence? Curr Urol 2010; 4: 15–17.